Sonidegib is used to treat basic cell cancer. Sonidegib may be used for objectives not listed in this medication overview. Sonidegib can cause serious abnormality or stillbirth if the mom or papa is taking sonidegib at the time of fertilization or while pregnant. Both women and men utilizing this medicine must use effective birth control to avoid maternity. Use effective contraception to stop maternity while you are using this medication and for at least 20 months after your last dose. If you are a man, constantly use a condom during sex with a woman who is pregnant or is able to get pregnant, even if you have had a birth control. Keep utilizing condoms while you are taking sonidegib and for a minimum of 8 months after your last dose. You will require to have unfavorable maternity test prior to you start taking sonidegib. Sonidegib can cause severe abnormality or stillbirth if the mother or papa is taking this medication at the time of conception or throughout pregnancy. Both men and women utilizing this medication must use efficient birth control to protect against maternity. Take sonidegib on an empty stomach, at least 1 hr prior to or 2 hours after a meal. You will require regular clinical tests to ensure sonidegib is not causing harmful effects. Your cancer therapies might be delayed based on the results of these tests. Take the medicine as soon as you can, however skip the missed out on dosage if it is nearly time for your following dosage.
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions
** If you believe that content on the Plex is summarised improperly, please, contact us, and we will get rid of it quickly; please, send an email with a brief explanation.
|24775005||C26H26F3N3O3||485.5||CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F||C[[email protected]@H]1CN(C[[email protected]@H](O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F||InChI=1S/C26H26F3N3O3/c1-16-14-32(15-17(2)34-16)24-12-9-20(13-30-24)31-25(33)23-6-4-5-22(18(23)3)19-7-10-21(11-8-19)35-26(27,28)29/h4-13,16-17H,14-15H2,1-3H3,(H,31,33)/t16-,17+||VZZJRYRQSPEMTK-CALCHBBNSA-N||N-[6-[(2S,6R)-2,6-dimethylmorpholin-4-yl]pyridin-3-yl]-2-methyl-3-[4-(trifluoromethoxy)phenyl]benzamide||5.8||485.19262619||485.19262619||63.7||691||0||1||8||5||35||0||2||2||0||0||0||0||1|